- Pacific Biosciences (NASDAQ: PACB) is projected to report a loss with an estimated EPS of -$0.13 for its upcoming quarterly earnings.
- The company remains unprofitable, reflected in a negative P/E ratio of -3.26, with revenue forecasts ranging from $40.70 million to $42.90 million.
- Despite a high debt-to-equity ratio of 297.29, Pacific Biosciences maintains a strong current ratio of 5.65, indicating solid short-term liquidity amidst cautious analyst sentiment.
Pacific Biosciences of California (NASDAQ: PACB), a leading company in the medical technology sector, specializes in developing and manufacturing advanced systems for gene sequencing. Investors are closely monitoring the company as it prepares to release its crucial quarterly earnings report on August 3, 2026, before the market opens.
The central focus for investors and analysts is on Pacific Biosciences' financial performance. For the upcoming quarter, Wall Street analysts estimate an earnings per share (EPS) of -$0.13. EPS is a key indicator of a company's profit per share of stock. A negative number signifies that the company is projected to report a financial loss for the period.
This negative earnings forecast aligns with Pacific Biosciences' current financial status. The company is not profitable, which is clearly shown by its negative price-to-earnings (P/E) ratio of -3.26. Additionally, revenue for the quarter is forecasted to be around $42.90 million, though other estimates place it at $40.70 million.
Analyst sentiment reflects this cautious outlook. As highlighted by Marketbeat, Pacific Biosciences has a consensus "Reduce" recommendation from five prominent research firms. This includes a recent "sell (e+)" stock rating from Weiss Ratings and a downgrade from "strong-buy" to "hold" by Zacks Research, showcasing mixed but generally wary expert opinions on the company's future.
Despite its unprofitability, Pacific Biosciences exhibits both financial strengths and financial weaknesses. The company has a high debt-to-equity ratio of 297.29, indicating a significant reliance on debt financing. However, its robust current ratio of 5.65 suggests that Pacific Biosciences possesses ample liquid assets to cover its short-term financial obligations, providing a measure of financial stability.